ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FBIO vs OSTX // REVENUE GROWTH (YOY)

Fortress Biotech Inc. (NASDAQ) VS. OS Therapies Incorporated (NYSE) • 15-METRIC TALLY: FBIO 3 — OSTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FBIO VS. OSTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FBIO OSTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 66.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -21.07% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 58.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 9.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 1.00% 0.00% +1.00 FBIO /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 FBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.7 33.8 +4.85 FBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $66.7M $67.6M -$882.5K OSTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FBIO REV OSTX REV FBIO GROSS % OSTX GROSS % FBIO FCF OSTX FCF
FY 2025 $63.3M $0 66.9% — -$65.8M -$14.2M
FY 2024 $57.7M $0 63.8% — -$80.2M -$7.3M
FY 2023 $84.5M $0 — — -$128.2M -$3.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FBIO // BETA —
OSTX // BETA —